Search Results

If you’re in GPCR discovery or biotech R&D, this is a masterclass in turning deep science into scalable

Pairaudeau, CTO of Exscientia discuss transforming drug discovery using their AI-driven platform Salipro Biotech

26RFa by the pyroglutamylated RFamide peptide receptor Industry News NanoImaging Services and Cube Biotech

with your topic suggestions 🆕 Weekly new releases to stay ahead of the science 🧠 Content built for biotech

GPCR scientists, translational pharmacologists, biotech discovery teams, platform company leaders, and

GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Kenakin Content trusted by biotech, pharma, and academia 💎 $2999/year — one conference cost = a full

Mid-2025 How GPCR agonists, including antibodies, are shaping the future of metabolic care Salipro Biotech

Kenakin Content trusted by biotech, pharma & academia 💎 $2999/year — one conference cost = a full

2023 Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion

Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023 InterAx Biotech

Industry News Orion Biotechnology at the AACR 2023. (April 20 - 21, 2023) Swiss Biotech Day (April 24 - 25, 2023) NEW ASPET 2023 - American Society for Pharmacology

(April 20 - 21, 2023) Swiss Biotech Day (April 24 - 25, 2023) ASPET 2023 - American Society for Pharmacology

Showcases Innovative AI-Driven Drug Design at BRIC AI 2023 Workshop Salipro Biotech AB Celebrates Milestones

Visit in its clinical phase 2b trial with AEF0117 for the treatment of cannabis use disorder Orion Biotechnology will be presenting at the 19th Biopharma Drug Discovery Nexus Salipro Biotech will participate in BioKorea2024

Kenakin Content trusted by biotech, pharma, and academia 💎 $2999/year — one conference cost = a full

Pharma’s INV-347 improves metabolic dysfunction in obese mice Aneesh Karatt Vellatt (CSO & Co-Founder, Maxion

neutrophils by promoting an alternative-like polarization during bacterial infection Industry News InterAx Biotech's

July 2022 "Orion Biotechnology and Peptilogics are pursuing AI-driven drug discovery to explore new functional

(April 20 - 21, 2023) NEW Swiss Biotech Day (April 24 - 25, 2023) SLAS Europe 2023 Conference and Exhibition

.- Jan Steyaert, scientific director of the VIB-VUB Center for Structural Biology, Vlaams Instituut Biotechnologie Brusle, Brussels, Belgium, has been named the winner of Brandeis’ 24th Jacob and Louise Gabbay Award in Biotechnology of one of the biggest classes of pharmaceutical targets by combining structural biology and advanced biotechnology

Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics

Biotherapeutics in Idiopathic Pulmonary Fibrosis Former execs from Pfizer obesity drug program have started a new biotech

in Upcoming Investor and Industry Conferences Sosei and IPJ to become Nxera Pharma from April Orion Biotechnology will be at the BIO CEO & Investor Conference Salipro Biotech AB will be at the Oxford Global’s Biologics

June 2022 "Ottawa, Canada, May 10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development

Secures VLAIO Grant Supporting Drug Discovery & Development In Endocrine And Metabolic Diseases How biotech

of Alcohol and Substance Use Disorders AbbVie recruits a GPCR team in Oxford, buying out a fledgling biotech

December 2021 "Ottawa, Ontario, Canada, Nov. 30, 2021 -- Orion Biotechnology, a clinical stage company

To solve this industry-wide problem, Orion Biotechnology (Orion) is introducing a novel solution driven technological advances related to the understanding of structure and activation mechanisms of GPCRs, the biotech investment community has injected significant funding into small biotech companies developing novel About Orion Biotechnology Orion’s mission is to unlock the therapeutic potential of previously undruggable For more information, follow Orion Biotechnology on LinkedIn or visit www.orionbiotechnology.com.

Nature Biotechnology   2003 , 21  (1), 86–89. https://doi.org/10.1038/nbt765 . (24)      Zwier, J.